Parkinson's Disease Epidemiology Forecast to 2032
25 janv. 2024 06h59 HE
|
Research and Markets
Dublin, Jan. 25, 2024 (GLOBE NEWSWIRE) -- The "Parkinson's Disease - Epidemiology Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. The report delivers an in-depth...
Multiple System Atrophy (MSA) - Market Insight, Epidemiology And Market Forecast 2023-2032
05 avr. 2023 06h03 HE
|
Research and Markets
Dublin, April 05, 2023 (GLOBE NEWSWIRE) -- The "Multiple System Atrophy (MSA) - Market Insight, Epidemiology And Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. ...
2021 U.S. Parkinson's Disease Epidemiology Report: 10-year Forecasts of Parkinson's Disease Epidemiology
23 août 2021 04h18 HE
|
Research and Markets
Dublin, Aug. 23, 2021 (GLOBE NEWSWIRE) -- The "Parkinson's Disease - US Epidemiology Forecast to 2030" drug pipelines has been added to ResearchAndMarkets.com's offering. The report delivers an...
Global Lewy Body Dementia Treatment Market (2020 to 2027) - Share, Size, Trends, Industry Analysis Report
19 mars 2021 08h03 HE
|
Research and Markets
Dublin, March 19, 2021 (GLOBE NEWSWIRE) -- The "Lewy Body Dementia Treatment Market Share, Size, Trends, Industry Analysis Report, By Drug Type; By Indication; By Distribution Channel; By Regions...
Seelos Therapeutics Announces Initiation of Preclinical Study of SLS-004 in Parkinson’s Disease
28 mai 2020 07h01 HE
|
Seelos Therapeutics, Inc.
NEW YORK, May 28, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos Therapeutics to Participate in the Benchmark Healthcare Virtual Conference
18 mai 2020 08h01 HE
|
Seelos Therapeutics, Inc.
NEW YORK, May 18, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos Therapeutics Announces Appointment of Judith Dunn to the Board of Directors
15 mai 2020 10h30 HE
|
Seelos Therapeutics, Inc.
NEW YORK, May 15, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos Therapeutics to Participate in the Jefferies Virtual Healthcare Conference
12 mai 2020 08h01 HE
|
Seelos Therapeutics, Inc.
NEW YORK, May 12, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos Therapeutics Provides Q1 2020 Business Update and Pipeline Developments
08 avr. 2020 09h01 HE
|
Seelos Therapeutics, Inc.
NEW YORK, April 08, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos Therapeutics Announces Closing of Public Offering of Common Stock
16 mars 2020 16h30 HE
|
Seelos Therapeutics, Inc.
NEW YORK, March 16, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...